Drug Trial Radar · NCT05408845
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
146
Planned (sponsor's estimate)
Start
Mar 3, 2023
Primary completion
Jul 31, 2028
Study completion Jul 31, 2033
Sponsor
- Lead sponsor
- NRG OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jun 7, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-positive salivary gland cancer that has come back (recurrent), that has spread from where it first started (primary site) to other places in the body, or cannot be removed by surgery (unresectable). This trial is also testing how well trastuzumab deruxtecan works in treating patients with HER2-low recurrent or metastatic salivary gland cancer. Trastuzumab is a form of targeted therapy because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by body's immune system. Trastuzumab emtansine contains trastuzumab, linked to a chemotherapy drug called emtansine. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers emtansine to kill them. Trastuzumab deruxtecan is a monoclonal antibody called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors and delivers deruxtecan to kill them. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Trastuzumab emtansine may work better compared to usual treatment of chemotherapy with docetaxel and trastuzumab or trastuzumab deruxtecan in treating patients with recurrent, metastatic or unresectable salivary gland cancer.
Conditions
- Metastatic Salivary Gland Carcinoma
- Recurrent Salivary Gland Carcinoma
- Stage III Major Salivary Gland Cancer AJCC v8
- Stage IV Major Salivary Gland Cancer AJCC v8
- Unresectable Salivary Gland Carcinoma
Interventions
Biopsy ProcedureProcedure
Undergo a biopsy
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo a CT scan
DocetaxelDrug
Given IV
Echocardiography TestProcedure
Undergo ECHO
Magnetic Resonance ImagingProcedure
Undergo MRI
Multigated Acquisition ScanProcedure
Undergo MUGA
Questionnaire AdministrationOther
Ancillary studies
TrastuzumabBiological
Given IV
Trastuzumab DeruxtecanBiological
Given IV
Trastuzumab EmtansineBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS) (HER2-Positive Cohort)Time frame: From randomization to disease progression or death due to any cause, whichever occurs first, assessed up to 5 years
- Objective response rate (ORR) (HER2-Low Expressing Cohort)Time frame: From the start of treatment up to a year or until the progression of disease, unacceptable toxicity, physician discretion to discontinue treatment, or patient withdrawal of consent, whichever occurs first.), assessed up to 5 years
Locations
154 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Active not recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Active not recruiting
Kaiser Permanente Dublin
Dublin, California · Recruiting
Kaiser Permanente-Fremont
Fremont, California · Recruiting
Kaiser Permanente Fresno Orchard Plaza
Fresno, California · Recruiting
Kaiser Permanente-Fresno
Fresno, California · Recruiting
City of Hope at Irvine Lennar
Irvine, California · Active not recruiting
Kaiser Permanente- Modesto MOB II
Modesto, California · Recruiting
Kaiser Permanente-Modesto
Modesto, California · Recruiting
Kaiser Permanente-Oakland
Oakland, California · Recruiting
Stanford Cancer Institute Palo Alto
Palo Alto, California · Recruiting
Kaiser Permanente-Roseville
Roseville, California · Recruiting
Kaiser Permanente Downtown Commons
Sacramento, California · Recruiting
Kaiser Permanente-South Sacramento
Sacramento, California · Recruiting
Kaiser Permanente-San Francisco
San Francisco, California · Recruiting
UCSF Medical Center-Mission Bay
San Francisco, California · Suspended
Kaiser Permanente-Santa Teresa-San Jose
San Jose, California · Recruiting
Kaiser Permanente San Leandro
San Leandro, California · Recruiting
Kaiser San Rafael-Gallinas
San Rafael, California · Recruiting
Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California · Recruiting
Kaiser Permanente-Santa Rosa
Santa Rosa, California · Recruiting
Kaiser Permanente-South San Francisco
South San Francisco, California · Recruiting
Kaiser Permanente-Vallejo
Vallejo, California · Recruiting
Kaiser Permanente-Walnut Creek
Walnut Creek, California · Recruiting
UCHealth University of Colorado Hospital
Aurora, Colorado · Recruiting
UCHealth Highlands Ranch Hospital
Highlands Ranch, Colorado · Recruiting
Miami Cancer Institute
Miami, Florida · Recruiting
Emory University Hospital Midtown
Atlanta, Georgia · Recruiting
Kaiser Permanente Moanalua Medical Center
Honolulu, Hawaii · Recruiting
Saint Luke's Cancer Institute - Boise
Boise, Idaho · Recruiting
Saint Luke's Cancer Institute - Fruitland
Fruitland, Idaho · Recruiting
Saint Luke's Cancer Institute - Meridian
Meridian, Idaho · Recruiting
Saint Luke's Cancer Institute - Nampa
Nampa, Idaho · Recruiting
Saint Luke's Cancer Institute - Twin Falls
Twin Falls, Idaho · Recruiting
Carle at The Riverfront
Danville, Illinois · Recruiting
Carle Physician Group-Effingham
Effingham, Illinois · Recruiting
Carle Physician Group-Mattoon/Charleston
Mattoon, Illinois · Recruiting
Memorial Hospital East
Shiloh, Illinois · Recruiting
Carle Cancer Center
Urbana, Illinois · Recruiting
McFarland Clinic - Ames
Ames, Iowa · Active not recruiting
Showing 40 of 154 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.